Low Density Lipoproteins as Drug Carriers in the Therapy of Macrophage-Associated Diseases

Mankertz, Joachim; Nündel, M.; Baeyer, Hans von; Riedel, E

doi:10.1006/bbrc.1997.7625

Cited by 10 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One viable way is to redirect LDL to scavenger receptors on cells of the monocyte/macrophage system, which are not down regulated by cholesterol accumulation. Lipoprotein rerouting can be achieved by modifying the LDL particle, for instance by acetylation, methylation, derivatization of lysine residues on apo-B100 or by oxidative modifications of LDL [49]. Such chemically modified LDL can be further loaded with drugs or contrast agents to be selectively taken up by different classes of scavenger receptors on macrophages, including lectin-like ox-LDL receptor (LOX1), scavenger receptor class A (SR-A) or SR-B1.…”

Section: Ldl Related Particles For Drug Delivery and Imagingmentioning

confidence: 99%

Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging

Almer¹,

Mangge²,

Zimmer³

et al. 2015

CMC

View full text Add to dashboard Cite

The integration of lipoprotein-related or apolipoprotein-targeted nanoparticles as pharmaceutical carriers opens new therapeutic and diagnostic avenues in nanomedicine. The concept is to exploit the intrinsic characteristics of lipoprotein particles as being the natural transporter of apolar lipids and fat in human circulation. Discrete lipoprotein assemblies and lipoprotein-based biomimetics offer a versatile nanoparticle platform that can be manipulated and tuned for specific medical applications. This article reviews the possibilities for constructing drug loaded, reconstituted or artificial lipoprotein particles. The advantages and limitations of lipoprotein-based delivery systems are critically evaluated and potential future challenges, especially concerning targeting specificity, concepts for lipoprotein rerouting and design of innovative lipoprotein mimetic particles using apolipoprotein sequences as targeting moieties are discussed. Finally, the review highlights potential medical applications for lipoprotein-based nanoparticle systems in the fields of cardiovascular research, cancer therapy, gene delivery and brain targeting focusing on representative examples from literature.

show abstract

Section: Ldl Related Particles For Drug Delivery and Imagingmentioning

confidence: 99%

Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging

Almer¹,

Mangge²,

Zimmer³

et al. 2015

CMC

View full text Add to dashboard Cite

show abstract

“…Показано, что в условиях воспаления и при инфицировании M. tuberculosis в макрофагах активируются ЛНП-рецепторы [9,10]. Поэтому ассоциация рифампицина с ЛНП могла бы способствовать его доставке в макрофаги и действию на персистирующие в них бактерии [11].…”

unclassified

“…В настоящей работе исследовали влияние включения рифампицина в данную наносистему на его распределение в плазме между различными классами липопротеинов и белковой фракцией при инкубации in vitro, с целью потенциальной оценки возможности его транспорта в альвеолярные макрофаги [11], наряду с обусловленным олеатом отрицательным зарядом наночастиц [13].…”

unclassified

“…Существенным фактором для этого является и большее сродство рифампицина к ЛНП (рисунок). В свете данных о поглощении макрофагами ЛНП путём рецепторного взаимодействия и активации этих рецепторов при воспалительных процессах [9,10], связывание рифампицина с ЛНП создаёт возможность использования этих естественных путей транспорта для доставки лекарства в поражённые микобактериями макрофаги [11]. Следовательно, разработанная транспортная наносистема в кровяном русле может обеспечить преимущественное связывание рифампицина с ЛНП, повышая (по сравнению со свободным рифампицином) его доставку в макрофаги, в дополнении к отрицательному заряду поверхности наночастиц [3][4][5].…”

unclassified

See 1 more Smart Citation

Interaction of rifampicin embedded in phospholipid nanoparticles with blood plasma lipoproteins

Sanzhakov

et al. 2014

BIOMED KHIM

View full text Add to dashboard Cite

The drug formulations of antituberculous remedy rifampicin in nanoparticles less than 30 nm based on soy phosphatidylcholine and sodium oleate was elaborated in Institute of Biomedical Chemistry. The distribution of rifampicin in blood plasma fractions after incubation with this formulation and with free rifampicin was studied. This goal was stimulated by the literature data about activation of macrophages LDL receptors in cases of M. tuberculosis infection. Plasma was incubated 30 min with free rifampicin or rifampicin encapsulated into the nanoformulation followed by ultracentrifugation and subsequent rifampicin determination by HPLC in lipoprotein fractions. In the case of free rifampicin it appeared mainly in the plasma protein fraction and in HDL (41% and 38%, correspondentely). But after incubation of rifampicin in nanoparticles the drug redistribution was observed. Its proportion in these factions decreased 2-3-fold, and it was found mainly in LDL (60% as compared with 21% for free rifampicin). The increased association of rifampicin encapsulated into phospholipid nanoparticles with LDL is considered as facilitating factor for macrophages delivery and thus for antituberculosis efficiency as well

show abstract

“…Their metabolism involves internalisation by means of LDL receptors present on almost all cells of the organism, through the lipoprotein Apo B present in the LDL and in cells belonging to the monocytes-macrophage system by means of scavenger receptors(Mankertz et al 1997;. Chemical modifications typical of the metabolism of Apo B, glycosylation, acetylation, derivatisation to aldehyde and oxidation, alter the affinity of LDLs for scavenger receptors of phagocytic cells.…”

mentioning

confidence: 99%

Estudio de la penetración de agente antiinfecciosos en macrófagos utilizando eritrocitos portadores

Cuesta¹

View full text Add to dashboard Cite

show abstract

Low Density Lipoproteins as Drug Carriers in the Therapy of Macrophage-Associated Diseases

Cited by 10 publications

References 7 publications

Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging

Lipoprotein-Related and Apolipoprotein-Mediated Delivery Systems for Drug Targeting and Imaging

Interaction of rifampicin embedded in phospholipid nanoparticles with blood plasma lipoproteins

Estudio de la penetración de agente antiinfecciosos en macrófagos utilizando eritrocitos portadores

Contact Info

Product

Resources

About